It pays to join the ARC COVID-19 booster trial

ARC Clinical Research is currently enrolling participants in an updated booster vaccine trial targeting COVID-19 variants. And participants will be paid as compensation for their time and travel.

"We are hoping to find that we can effectively alter the vaccine to target whatever variant we are working on targeting and that it will have the same impact the Pfizer vaccine had,” said Dr. Amy SiegelInternal Medicine at ARC Far West and principal investigator at ARC Clinical Research William Cannon.

In recent interviews on Texas News Today and Spectrum News, Dr. Siegel said, "We’re doing a trial for a modified Pfizer vaccine.” She adds, "It’s made by BNT. It’s the company that made the Pfizer vaccine in conjunction with Pfizer and it’s geared towards a couple of variants: Alpha and Delta.”

Why participate in a trial?

“I was super excited to go through the process,” said Dr. Sunaina Suhag, a participant of the phase two trial of the initial Pfizer COVID-19 vaccine. “I just remember being really excited to make an impact.”

pediatrician at ARC East 7th, Dr. Suhag admits going to her first trial she did feel some hesitancy but trusted in the process. “I think from a side effect, a risk standpoint, we know what the risks are pretty well, at this point,” she said. "It’ll be about what the benefits will be, and I think those will be super invaluable to us.”

About this trial

ARC Clinical Research is one of the select sites across the country to participate in a BioNTech COVID-19 vaccine study testing an updated Pfizer‐BioNTech vaccine targeting specific variants.

This study consists of two parts. One part will evaluate the safety and efficacy of the booster injection (third shot) containing multivalent vaccine (two virus strains). The second part will evaluate the safety and efficacy of a booster injection of a monovalent vaccine (one virus strain). The results of the two parts will be compared to those who were previously vaccinated with the Pfizer‐BioNTech vaccine currently approved by the Food and Drug Administration (FDA).

The trial is enrolling healthy adults between 18 to 85 years old who are currently unvaccinated for COVID-19 and have no history of a COVID-19 infection. Trial participants will be compensated $100 per visit for time and travel.

What you need to know to participate

  • Volunteers need to be between the ages of 18 to 85, have not had a COVID vaccine and have no history of COVID-19 infection.
  • ARC Clinical Research is the only site in Central Texas recruiting for the BioNTech trial. To participate in the trial, call 512-225-5931 or log on to ARC Clinical Research.
  • Participants receive compensation.

Tags: COVID-19 vaccine trial, Spectrum 1 New, Texas News Today

More on this Topic

First dose dos and don’ts

In this recent article in the online magazine The List, Natalie A. Williams, MDARC Family Medicine physician, talks about vaccine efficacy between the first and second doses of the Pflizer and Moderna COVID-19 vaccines, as well as what a return to "normalcy" will look like and what it will take for us all to stay safe, post-vaccine. Read More

ARC Clinical Research starts to enroll children 12-17 years old for COVID-19 Vaccine Trial

ARC Clinical Research, ARC’s medical research department that enables clinical trials, announces it looks to enroll children 12-17 years old in Pfizer’s COVID-19 vaccine clinical trial that began in early August 2020.

ARC COVID-19 vaccine trial to continue on schedule

In response to announcements of the possible release of a COVID-19 vaccine as early as October 2020, ARC has said it will continue its vaccine trial. Dr. Anas Daghestani, CEO of ARC has said, “Our timeline is still the same.”

Austin Regional Clinic to begin COVID-19 vaccine trial

Austin Regional Clinic recently began recruiting for a COVID-19 vaccine clinical trial set to begin this month. “It is the top priority of the US and the world to find a successful vaccine to prevent the infection and spread of COVID-19,” said Dr. Gretchen Crook, principal investigator for ARC Clinical Research.